03:41 PM EST - Knight Therapeutics Inc. : And Braeburn Pharmaceuticals, Inc. announced today that they have entered into an agreement whereby Knight received the exclusive rights to commercialize PROBUPHINE® in Canada. PROBUPHINE® is an investigational subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment, promoting patient compliance and retention as well as helping to prevent accidental paediatric exposure. Knight Therapeutics Inc.
shares T.GUD are trading unchanged at $6.77.
